Biomarker Partnering Terms and Agreements: Strongly Driven by Advances in Personalized Medication for Chronic Diseases
Burgeoning advances in personalized medication to target specific disease triggers and develop corresponding therapeutics has necessitated biomarker deals across pharmaceutical landscape. An upsurge in coalitions, acquisitions, buy-outs, as well as licensing in pharmaceutical industry favoring innovations in therapeutics and drug discovery has spurred growth in global biomarker partnering deals. These aforementioned market highlights have been meticulously elaborated in Market Research Hub's (MRH) recent report addition titled, 'Global Biomarker Partnering Terms and Agreements 2010-2018: Deal trends, players and financials' included in...
View full press release